CN101208340B - 作为β-肾上腺素能受体激酶1抑制剂的吡唑并吡啶衍生物 - Google Patents

作为β-肾上腺素能受体激酶1抑制剂的吡唑并吡啶衍生物 Download PDF

Info

Publication number
CN101208340B
CN101208340B CN200680023397XA CN200680023397A CN101208340B CN 101208340 B CN101208340 B CN 101208340B CN 200680023397X A CN200680023397X A CN 200680023397XA CN 200680023397 A CN200680023397 A CN 200680023397A CN 101208340 B CN101208340 B CN 101208340B
Authority
CN
China
Prior art keywords
alkyl
alkylene
formula
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680023397XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101208340A (zh
Inventor
H·施泰因哈根
J·胡贝尔
K·里特
B·皮拉德
K·比耶尔加尔德
M·帕特克
M·斯姆尔奇纳
L·魏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SRL
Original Assignee
Sanofi Aventis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis SpA filed Critical Sanofi Aventis SpA
Publication of CN101208340A publication Critical patent/CN101208340A/zh
Application granted granted Critical
Publication of CN101208340B publication Critical patent/CN101208340B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200680023397XA 2005-06-27 2006-06-13 作为β-肾上腺素能受体激酶1抑制剂的吡唑并吡啶衍生物 Expired - Fee Related CN101208340B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05013774.4 2005-06-27
EP05013774 2005-06-27
PCT/EP2006/005649 WO2007000241A1 (en) 2005-06-27 2006-06-13 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1

Publications (2)

Publication Number Publication Date
CN101208340A CN101208340A (zh) 2008-06-25
CN101208340B true CN101208340B (zh) 2010-12-22

Family

ID=35395578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680023397XA Expired - Fee Related CN101208340B (zh) 2005-06-27 2006-06-13 作为β-肾上腺素能受体激酶1抑制剂的吡唑并吡啶衍生物

Country Status (30)

Country Link
US (1) US7910602B2 (https=)
EP (1) EP1899333B1 (https=)
JP (1) JP5010594B2 (https=)
KR (1) KR20080020638A (https=)
CN (1) CN101208340B (https=)
AR (1) AR054514A1 (https=)
AT (1) ATE423118T1 (https=)
AU (1) AU2006264044A1 (https=)
BR (1) BRPI0612320A2 (https=)
CA (1) CA2611296A1 (https=)
CY (1) CY1110464T1 (https=)
DE (1) DE602006005242D1 (https=)
DK (1) DK1899333T3 (https=)
ES (1) ES2322197T3 (https=)
HR (1) HRP20090244T2 (https=)
IL (1) IL188381A0 (https=)
MA (1) MA29498B1 (https=)
MX (1) MX2007015829A (https=)
MY (1) MY139016A (https=)
NO (1) NO20080392L (https=)
NZ (1) NZ564757A (https=)
PL (1) PL1899333T3 (https=)
PT (1) PT1899333E (https=)
RS (1) RS50821B (https=)
RU (1) RU2415855C2 (https=)
SI (1) SI1899333T1 (https=)
TW (1) TW200800982A (https=)
UY (1) UY29632A1 (https=)
WO (1) WO2007000241A1 (https=)
ZA (1) ZA200709853B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815438A (en) 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
CN112955450A (zh) * 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
EP4041730A1 (en) 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
WO2024137671A1 (en) * 2022-12-20 2024-06-27 Exelixis, Inc. Compounds that inhibit pkmyt1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1675209A (zh) * 2002-08-07 2005-09-28 三菱制药株式会社 二氢吡唑并吡啶化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034563A1 (en) * 1994-06-16 1995-12-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
ATE355841T1 (de) * 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1675209A (zh) * 2002-08-07 2005-09-28 三菱制药株式会社 二氢吡唑并吡啶化合物

Also Published As

Publication number Publication date
NZ564757A (en) 2009-12-24
DE602006005242D1 (de) 2009-04-02
UY29632A1 (es) 2007-01-31
PT1899333E (pt) 2009-04-23
MX2007015829A (es) 2008-02-22
RU2008102970A (ru) 2009-08-10
MY139016A (en) 2009-08-28
ATE423118T1 (de) 2009-03-15
CA2611296A1 (en) 2007-01-04
ES2322197T3 (es) 2009-06-17
CN101208340A (zh) 2008-06-25
JP5010594B2 (ja) 2012-08-29
TW200800982A (en) 2008-01-01
WO2007000241A1 (en) 2007-01-04
KR20080020638A (ko) 2008-03-05
NO20080392L (no) 2008-02-28
RU2415855C2 (ru) 2011-04-10
US20080227777A1 (en) 2008-09-18
RS50821B (sr) 2010-08-31
MA29498B1 (fr) 2008-05-02
EP1899333B1 (en) 2009-02-18
IL188381A0 (en) 2008-04-13
US7910602B2 (en) 2011-03-22
HRP20090244T2 (hr) 2009-07-31
EP1899333A1 (en) 2008-03-19
AR054514A1 (es) 2007-06-27
SI1899333T1 (sl) 2009-08-31
CY1110464T1 (el) 2015-04-29
DK1899333T3 (da) 2009-06-15
ZA200709853B (en) 2008-12-31
JP2008543957A (ja) 2008-12-04
BRPI0612320A2 (pt) 2010-11-09
HRP20090244T1 (en) 2009-06-30
AU2006264044A1 (en) 2007-01-04
PL1899333T3 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
US7910602B2 (en) Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1
CN107406426B (zh) 作为rock抑制剂的环状脲类
US6403588B1 (en) Imidazopyridine derivatives
EP1703905B1 (en) Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors
BR112019015707A2 (pt) Composto, composição farmacêutica. uso de um composto, combinação de um composto e dispositivo
TW201141483A (en) Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
WO2006088246A1 (ja) Ｇｐｒ３４受容体機能調節剤
CN107108575B (zh) 作为抗组胺剂的新型苯并咪唑衍生物
CN112752757B (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
CN103443076A (zh) 在3位双取代的吲哚-2-酮衍生物、其制备和其治疗应用
CN118159535A (zh) 小分子sting拮抗剂
CA2623154A1 (en) Novel fused pyrrole derivative
CA2211189A1 (en) Substituted 1,4-piperazine-heteroaryl derivatives as 5-ht1d receptor agonists
US6169107B1 (en) Indoloylguanidine derivatives
WO2007076286A2 (en) Chemical compounds
CN106928252B (zh) 一种抑制rock的化合物及其制备方法与应用
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
HK1122550A (en) Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1
EP0906308A1 (en) Azetidine, pyrrolidine and piperidine derivatives as 5-ht1d receptor agonists
CN111065635B (zh) 作为mth1抑制剂的新型嘧啶衍生物
JPH107658A (ja) スルホニルウレイドピラゾール誘導体
HK1215026A1 (zh) 作为perk抑制剂的n-(2，3-二氢-1h-吡咯并[2，3-b]吡啶-5-基)-4-喹唑啉胺和n-(2，3-二氢-1h-吲哚-5-基)-4-喹唑啉胺衍生物
HK1098047B (en) Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122550

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101222

Termination date: 20110613

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1122550

Country of ref document: HK